This trade activity should not be overlooked: Aeglea BioTherapeutics Inc. (AGLE)

Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) stock jumped 4.29% on Monday to $0.51 against a previous-day closing price of $0.49. With 0.33 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.03 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.5200 whereas the lowest price it dropped to was $0.4900. The 52-week range on AGLE shows that it touched its highest point at $4.54 and its lowest point at $0.34 during that stretch. It currently has a 1-year price target of $2.75. Beta for the stock currently stands at 1.63.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AGLE was down-trending over the past week, with a drop of -2.85%, but this was up by 46.44% over a month. Three-month performance surged to 7.25% while six-month performance rose 19.91%. The stock lost -88.08% in the past year, while it has gained 14.45% so far this year. A look at the trailing 12-month EPS for AGLE yields -1.15 with Next year EPS estimates of -0.75. For the next quarter, that number is -0.20. This implies an EPS growth rate of 34.00% for this year and 30.60% for next year.

Float and Shares Shorts:

At present, 94.20 million AGLE shares are outstanding with a float of 60.28 million shares on hand for trading. On Dec 29, 2022, short shares totaled 1.0 million, which was 1.63% higher than short shares on Nov 29, 2022. In addition to Mr. Michael C. Hanley M.B.A. as the firm’s Chief Commercial Officer & Chief Bus. Officer, Mr. Jeffrey M. Goldberg serves as its Pres, CEO & Director.

Institutional Ownership:

Through their ownership of 82.48% of AGLE’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 54.13% of AGLE, in contrast to 18.91% held by mutual funds. Shares owned by individuals account for 11.44%. As the largest shareholder in AGLE with 7.59% of the stake, Sio Capital Management LLC holds 4,668,536 shares worth 4,668,536. A second-largest stockholder of AGLE, Suvretta Capital Management LLC, holds 4,059,894 shares, controlling over 6.60% of the firm’s shares. Nantahala Capital Management LLC is the third largest shareholder in AGLE, holding 3,710,778 shares or 6.03% stake. With a 2.32% stake in AGLE, the Pictet – Biotech is the largest stakeholder. A total of 1,425,961 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.08% of AGLE stock, is the second-largest Mutual Fund holder. It holds 1,282,021 shares valued at 0.58 million. Pictet – Global Megatrend Selecti holds 1.37% of the stake in AGLE, owning 843,776 shares worth 0.38 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, AGLE reported revenue of $625.00k and operating income of -$22.42M. The EBITDA in the recently reported quarter was -$22.05M and diluted EPS was -$0.27.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AGLE since 6 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AGLE analysts setting a high price target of $6.00 and a low target of $1.00, the average target price over the next 12 months is $2.75. Based on these targets, AGLE could surge 1076.47% to reach the target high and rise by 96.08% to reach the target low. Reaching the average price target will result in a growth of 439.22% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. AGLE will report FY 2022 earnings on 03/05/2024. Analysts have provided yearly estimates in a range of -$0.97 being high and -$1.40 being low. For AGLE, this leads to a yearly average estimate of -$1.08. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Aeglea BioTherapeutics Inc. surprised analysts by $0.08 when it reported -$0.17 EPS against a consensus estimate of -$0.25. The surprise factor in the prior quarter was $0.05. Based on analyst estimates, the high estimate for the next quarter is -$0.18 and the low estimate is -$0.36. The average estimate for the next quarter is thus -$0.23.

Summary of Insider Activity:

Insiders traded AGLE stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 7 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 417,945 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *